Short-term effectiveness of radiochemoembolization for selected hepatic metastases with a combination protocol

World Journal of Gastroenterology

Volumn 18, Issue 37, 2012, Pages 5249-5259

  Akhlaghpoor, Shahram ^a   Aziz Ahari, Alireza ^a   Amoui, Mahasti ^b   Tolooee, Shahnaz ^c   Poorbeigi, Hossein ^c   Sheybani, Shahab ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c University of Science and Culture   (Iran)

Author keywords

Hepatic metastasis; Outcome; Phosphorus radioisotopes; Radiochemoembolization; Treatment

Indexed keywords

CISPLATIN; DOXORUBICIN; MITOMYCIN C; RADIOISOTOPE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; BREAST CANCER; CARCINOID; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FEVER; FOLLOW UP; HUMAN; LIVER BIOPSY; LIVER METASTASIS; LUNG CANCER; MALE; RADIOCHEMOEMBOLIZATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

EID: 84867807487     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i37.5249     Document Type: Article

References (62)

1. Martin RC, Robbins K, Tomalty D, O'Hara R, Bosnjakovic P, Padr R, Rocek M, Slauf F, Scupchenko A, Tatum C. Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report. World J Surg Oncol 2009; 7: 80
2. Gee M, Soulen MC. Chemoembolization for hepatic metastases. Tech Vasc Interv Radiol 2002; 5: 132-140
3. Soulen MC. Chemoembolization of hepatic malignancies. Oncology (Williston Park) 1994; 8: 77-84; discussion 84, 89-90 passim
4. Koumenis C, Alarcon R, Hammond E, Sutphin P, Hoffman W, Murphy M, Derr J, Taya Y, Lowe SW, Kastan M, Giaccia A. Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol Cell Biol 2001; 21: 1297-1310
5. Kruskal JB, Hlatky L, Hahnfeldt P, Teramoto K, Stokes KR, Clouse ME. In vivo and in vitro analysis of the effectiveness of doxorubicin combined with temporary arterial occlusion in liver tumors. J Vasc Interv Radiol 1993 741-747
6. Ibrahim SM, Lewandowski RJ, Sato KT, Gates VL, Kulik L, Mulcahy MF, Ryu RK, Omary RA, Salem R. Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol 2008; 14: 1664-1669
7. Miller FH, Keppke AL, Reddy D, Huang J, Jin J, Mulcahy MF, Salem R. Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET. AJR Am J Roentgenol 2007; 188: 776-783
8. Sato KT, Lewandowski RJ, Mulcahy MF, Atassi B, Ryu RK, Gates VL, Nemcek AA, Barakat O, Benson A, Mandal R, Talamonti M, Wong CY, Miller FH, Newman SB, Shaw JM, Thurston KG, Omary RA, Salem R. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres--safety, efficacy, and survival. Radiology 2008; 247: 507-515
9. Salem R, Thurston KG. Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 3: comprehensive literature review and future direction. J Vasc Interv Radiol 2006; 17: 1571-1593
10. Kosmider S, Tan TH, Yip D, Dowling R, Lichtenstein M, Gibbs P. Radioembolization in combination with systemic chemotherapy as first-line therapy for liver metastases from colorectal cancer. J Vasc Interv Radiol 2011; 22: 780-786
11. Nicolay NH, Berry DP, Sharma RA. Liver metastases from colorectal cancer: radioembolization with systemic therapy. Nat Rev Clin Oncol 2009; 6: 687-697
12. Wang XM, Yin ZY, Yu RX, Peng YY, Liu PG, Wu GY. Preventive effect of regional radiotherapy with phosphorus-32 glass microspheres in hepatocellular carcinoma recurrence after hepatectomy. World J Gastroenterol 2008; 14: 518-523
13. Gao W, Liu L, Teng GJ, Feng GS, Tong GS, Gao NR. Internal radiotherapy using 32P colloid or microsphere for refractory solid tumors. Ann Nucl Med 2008; 22: 653-660
14. Goh AS, Chung AY, Lo RH, Lau TN, Yu SW, Chng M, Satchithanantham S, Loong SL, Ng DC, Lim BC, Connor S, Chow PK. A novel approach to brachytherapy in hepatocellular carcinoma using a phosphorous32 (32P) brachytherapy delivery device--a first-in-man study. Int J Radiat Oncol Biol Phys 2007; 67: 786-792
15. Wang XD, Yang RJ, Cao XC, Tan J, Li B. Dose delivery estimated by bremsstrahlung imaging and partition model correlated with response following intra-arterial radioembolization with 32P-glass microspheres for the treatment of hepatocellular carcinoma. J Gastrointest Surg 2010; 14: 858-866
16. Yan L, Li L, Chen S. [Radioembolization with 32P-labelled glass microspheres for advanced hepatocellular carcinoma]. Zhonghua Waike Zazhi 1996; 34: 526-529
17. Zhang K, Loong SL, Connor S, Yu SW, Tan SY, Ng RT, Lee KM, Canham L, Chow PK. Complete tumor response following intratumoral 32P BioSilicon on human hepatocellular and pancreatic carcinoma xenografts in nude mice. Clin Cancer Res 2005; 11: 7532-7537
18. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60
19. Gonsalves CF, Brown DB. Chemoembolization of hepatic malignancy. Abdom Imaging 2009; 34: 557-565
20. Firusian N, Dempke W. An early phase II study of intratumoral P-32 chromic phosphate injection therapy for patients with refractory solid tumors and solitary metastases. Cancer 1999; 85: 980-987
21. Vogl TJ, Naguib NN, Nour-Eldin NE, Eichler K, Zangos S, Gruber-Rouh T. Transarterial chemoembolization (TACE) with mitomycin C and gemcitabine for liver metastases in breast cancer. Eur Radiol 2010; 20: 173-180
22. Brown DB, Gould JE, Gervais DA, Goldberg SN, Murthy R, Millward SF, Rilling WS, Geschwind JF, Salem R, Vedantham S, Cardella JF, Soulen MC. Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Interv Radiol 2009; 20: S425-S434
23. Mortazavi SM, Asadollahi S, Farzan M, Shahriaran S, Aghili M, Izadyar S, Lak M. (32)P colloid radiosynovectomy in treatment of chronic haemophilic synovitis: Iran experience. Haemophilia 2007; 13: 182-188
24. Pattillo RA, Collier BD, Abdel-Dayem H, Ozker K, Wilson C, Ruckert AC, Hamilton K. Phosphorus-32-chromic phosphate for ovarian cancer: I. Fractionated low-dose intraperitoneal treatments in conjunction with platinum analog chemotherapy. J Nucl Med 1995; 36: 29-36
25. Young RC, Brady MF, Nieberg RK, Long HJ, Mayer AR, Lentz SS, Hurteau J, Alberts DS. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group study. J Clin Oncol 2003; 21: 4350-4355
26. Liu L, Feng GS, Gao H, Tong GS, Wang Y, Gao W, Huang Y, Li C. Chromic-P32 phosphate treatment of implanted pancreatic carcinoma: mechanism involved. World J Gastroenterol 2005; 11: 2101-2108
27. Lee I, Wallner PE. Evaluation of cellular uptake, tumor retention, radiation response, and tumor pathophysiology in experimental solid tumors after an intratumoral infusion of colloidal 32P. Cancer 1997; 80: 2611-2617
28. Kim JY, Bom HS, Kim YJ, Choi W. Adjuvant internal hepatic radiotherapy using colloidal 32P chromic phosphate in colorectal cancer. Radiat Med 1990; 8: 246-249
29. Mantravadi RV, Spigos DG, Tan WS, Felix EL. Intraarterial yttrium 90 in the treatment of hepatic malignancy. Radiology 1982; 142: 783-786
30. Liapi E, Geschwind JF. Chemoembolization for primary and metastatic liver cancer. Cancer J 2010: 156-162
31. Cividalli A, Ceciarelli F, Livdi E, Altavista P, Cruciani G, Marchetti P, Danesi DT. Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule. Int J Radiat Oncol Biol Phys 2002; 52: 1092-1098
32. Sharma RA, Van Hazel GA, Morgan B, Berry DP, Blanshard K, Price D, Bower G, Shannon JA, Gibbs P, Steward WP. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 2007; 25: 1099-1106
33. Pisters PW, Ballo MT, Fenstermacher MJ, Feig BW, Hunt KK, Raymond KA, Burgess MA, Zagars GK, Pollock RE, Benjamin RS, Patel SR. Phase I trial of preoperative concurrent doxorubicin and radiation therapy, surgical resection, and intraoperative electron-beam radiation therapy for patients with localized retroperitoneal sarcoma. J Clin Oncol 2003; 21: 3092-3097
34. Koukourakis MI, Koukouraki S, Giatromanolaki A, Kakolyris S, Georgoulias V, Velidaki A, Archimandritis S, Karkavitsas NN. High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas--rationale for combination with radiotherapy. Acta Oncol 2000; 39: 207-211
35. Koukourakis MI, Romanidis K, Froudarakis M, Kyrgias G, Koukourakis GV, Retalis G, Bahlitzanakis N. Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer: excellent tolerance using subcutaneous amifostine for cytoprotection. Br J Cancer 2002; 87: 385-392
36. Hsieh CI, Liu MC, Cheng SH, Liu TW, Chen CM, Chen CM, Tsou MH, Huang AT. Adjuvant sequential chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil (ACMF) with concurrent radiotherapy in resectable advanced breast cancer. Am J Clin Oncol 2000; 23: 122-127
37. Behr TM, Wulst E, Radetzky S, Blumenthal RD, Dunn RM, Gratz S, Rave-Fränk M, Schmidberger H, Raue F, Becker W. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type. Cancer Res 1997; 57: 5309-5319
38. Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010; 7: e1000267
39. Matzinger O, Roelofsen F, Mineur L, Koswig S, Van Der Steen-Banasik EM, Van Houtte P, Haustermans K, Radosevic-Jelic L, Mueller RP, Maingon P, Collette L, Bosset JF. Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014). Eur J Cancer 2009; 45: 2782-2791
40. Wolf M, Zehentmayr F, Niyazi M, Ganswindt U, Haimerl W, Schmidt M, Hölzel D, Belka C. Long-term outcome of mitomycin C-and 5-FU-based primary radiochemotherapy for esophageal cancer. Strahlenther Onkol 2010; 186: 374-381
41. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216
42. Forner A, Ayuso C, Varela M, Rimola J, Hessheimer AJ, de Lope CR, Reig M, Bianchi L, Llovet JM, Bruix J. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 2009; 115: 616-623
43. Peynircioǧlu B, Cil B, Bozkurt F, Aydemir E, Uǧur O, Balkanci F. Radioembolization for the treatment of unresectable liver cancer: initial experience at a single center. Diagn Interv Radiol 2010; 16: 70-78
44. Artinyan A, Nelson R, Soriano P, Chung V, Retseck J, Reynolds J, Marx H, Kim J, Wagman L. Treatment response to transcatheter arterial embolization and chemoembolization in primary and metastatic tumors of the liver. HPB (Oxford) 2008; 10: 396-404
45. Buijs M, Kamel IR, Vossen JA, Georgiades CS, Hong K, Geschwind JF. Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging. J Vasc Interv Radiol 2007; 18: 957-963
46. Stubbs RS, O'Brien I, Correia MM. Selective internal radiation therapy with 90Y microspheres for colorectal liver metastases: single-centre experience with 100 patients. ANZ J Surg 2006; 76: 696-703
47. Keppke AL, Salem R, Reddy D, Huang J, Jin J, Larson AC, Miller FH. Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. AJR Am J Roentgenol 2007; 188: 768-775
48. Buijs M, Vossen JA, Hong K, Georgiades CS, Geschwind JF, Kamel IR. Chemoembolization of hepatic metastases from ocular melanoma: assessment of response with contrastenhanced and diffusion-weighted MRI. AJR Am J Roentgenol 2008; 191: 285-289
49. Blanchard RJ, Morrow IM, Sutherland JB. Treatment of liver tumors with yttrium-90 microspheres alone. Can Assoc Radiol J 1989; 40: 206-210
50. Andrews JC, Walker SC, Ackermann RJ, Cotton LA, Ensminger WD, Shapiro B. Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. J Nucl Med 1994; 35: 1637-1644
51. Lim L, Gibbs P, Yip D, Shapiro JD, Dowling R, Smith D, Little A, Bailey W, Liechtenstein M. Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies. Intern Med J 2005; 35: 222-227
52. Yu M, Lewandowski RJ, Wong CY, Gates VL, Omary RA, Salem R. Yttrium-90 (SIR-Spheres microspheres) treatment for metastatic cancer to the liver: midterm results. Society of Interventional Radiology Conference; 2006 Mar; Toronto, Ontario, Canada. Available from: ULR: http://directory. sirweb.org/amabst/display.cfm?ID=1093
53. Szyszko T, Al-Nahhas A, Canelo R, Habib N, Jiao L, Wasan H, Pagou M, Tait P. Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: value of FDG PET versus computed tomography. Nucl Med Commun 2007; 28: 15-20
54. Stuart JE, Tan B, Myerson RJ, Garcia-Ramirez J, Goddu SM, Pilgram TK, Brown DB. Salvage radioembolization of liverdominant metastases with a resin-based microsphere: initial outcomes. J Vasc Interv Radiol 2008; 19: 1427-1433
55. Kennedy AS, McNeillie P, Dezarn WA, Nutting C, Sangro B, Wertman D, Garafalo M, Liu D, Coldwell D, Savin M, Jakobs T, Rose S, Warner R, Carter D, Sapareto S, Nag S, Gulec S, Calkins A, Gates VL, Salem R. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys 2009; 74: 1494-1500
56. Omed A, Lawrance JA, Murphy G, Laasch HU, Wilson G, Illidge T, Tipping J, Zivanovic M, Jeans S. A retrospective analysis of selective internal radiation therapy (SIRT) with yttrium-90 microspheres in patients with unresectable hepatic malignancies. Clin Radiol 2010; 65: 720-728
57. Cianni R, Urigo C, Notarianni E, Saltarelli A, D'Agostini A, Iozzino M, Dornbusch T, Cortesi E. Radioembolisation using yttrium 90 (Y-90) in patients affected by unresectable hepatic metastases. Radiol Med 2010; 115: 619-633
58. Diaco DS, Hajarizadeh H, Mueller CR, Fletcher WS, Pommier RF, Woltering EA. Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization. Am J Surg 1995; 169: 523-528
59. Drougas JG, Anthony LB, Blair TK, Lopez RR, Wright JK, Chapman WC, Webb L, Mazer M, Meranze S, Pinson CW. Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors. Am J Surg 1998; 175: 408-412
60. Tellez C, Benson AB, Lyster MT, Talamonti M, Shaw J, Braun MA, Nemcek AA, Vogelzang RL. Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer 1998; 82: 1250-1259
61. Ruutiainen AT, Soulen MC, Tuite CM, Clark TW, Mondschein JI, Stavropoulos SW, Trerotola SO. Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. J Vasc Interv Radiol 2007; 18: 847-855
62. Albert M, Kiefer MV, Sun W, Haller D, Fraker DL, Tuite CM, Stavropoulos SW, Mondschein JI, Soulen MC. Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer 2011; 117: 343-352